PubMed-compiled information sheet
This sheet was compiled from PubMed (NIH) abstracts using AI assistance. Every factual claim is cited to a real PubMed article (see the source list). It has not yet been human-reviewed — confirm with a healthcare provider before use.
Compiled from 13 PubMed articles · model: gemma4:31b
Summary
Background
Traditional uses
Active compounds
Mechanism of action
Clinical evidence
PS extract inhibited the production of IL-8 and TARC in human keratinocytes and reduced AD-like lesions in NC/Nga mice [PMID:28347830].
Combined extracts of Portulaca oleracea and Patrinia scabiosaefolia diminished UVB-induced inflammation and erythema in mice [PMID:39991764].
Dry extract of P. scabiosifolia demonstrated anxiolytic and sedative properties in male mice under acoustic stress [PMID:38164833].
Compounds patriniaol A and eudesmin exhibited moderate cytotoxicity against HCT-116 cells in vitro [PMID:32743961].
P. scabiosaefolia showed strong antibacterial activity by damaging the cell wall and membrane [PMID:36925724].
Safety & adverse effects
Evidence summary
PubMed sources
- 1.PMID: 33424592 (2020) — A Systematic Study of Mechanism of Sargentodoxa cuneata and Patrinia scabiosifolia Against Pelvic Inflammatory Disease With Dampness-Heat Stasis Syndrome via Network Pharmacology Approach. · Frontiers in pharmacology
- 2.PMID: 34299477 (2021) — Two New Iridoid Glucosides from the Whole Plant of Patrinia scabiosifolia Link. · Molecules (Basel, Switzerland)
- 3.PMID: 38164833 (2023) — Evaluation of the anxiolytic activity of dry extract of Patrinia scabiosifolia under acoustic stress. · European review for medical and pharmacological sciences
- 4.PMID: 31250551 (2019) — Chemical Composition of Patrinia scabiosifolia Flower Absolute and Its Migratory and Proliferative Activities in Human Keratinocytes. · Chemistry & biodiversity
- 5.PMID: 28347830